AsadBasheyMD

Hematology • Atlanta, GA

Hematologic Oncology, Myeloproliferative Disorder Hematology-Oncology

Director of Clinical Research for The Blood and Marrow Transplant Program at Northside Hospital.

Join to view full profile

Dr. Bashey is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Bashey's full profile

Already have an account?

Office
5670 Peachtree Dunwoody Rd Ne
Suite 1000
Atlanta, GA 30342
Phone+1 404-255-1930

Fax+1 404-459-8510

Education & Training

University of California (San Diego) Medical CenterFellowship, Hematology and Medical Oncology, 1993 - 1996
Univ Dundee- Fac MedClass of 1984

Certifications & Licensure

CA State Medical License 1994 - 2026
GA State Medical License 2005 - 2025
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Atlanta Magazine: Top Doctors Castle Connolly, 2013-2014, 2014-2022

Clinical Trials

Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer Start of enrollment: 2002 Dec 01
Completed
Phase 2
Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301) Start of enrollment: 2006 Jan 01
Completed
Phase 1, Phase 2
Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML) Start of enrollment: 2005 Jul 01
Completed
Phase 1, Phase 2
Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer Start of enrollment: 2008 Oct 01
Completed
Phase 2
Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer Start of enrollment: 2007 Apr 01
Completed
Phase 2
Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702) Start of enrollment: 2010 May 01
Completed
Phase 3
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant Start of enrollment: 2010 Dec 01
Terminated
Phase 2
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant Start of enrollment: 2011 Apr 20
Completed
Phase 3
Total Body Irradiation/Fludarabine Based Ablative Haploidentical Transplant for Hematologic Diseases Start of enrollment: 2011 Apr 01
Completed
Phase 2
Palonosetron, Ondansetron, and Dexamethasone for Delayed Nausea and Vomiting in Autologous Transplant Patients Start of enrollment: 2012 Feb 01
Completed
Phase 2
Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers Start of enrollment: 2012 Feb 27
Completed
Phase 1, Phase 2
Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant Start of enrollment: 2013 May 16
Completed
Phase 1
Nonmyeloablative Haploidentical Transplant Followed by MLN9708 Start of enrollment: 2014 Jul 15
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

844 citations
Lenalidomide after stem-cell transplantation for multiple myeloma
Philip L. McCarthy, Kouros Owzar, Craig C. Hofmeister, David D. Hurd, Hani Hassoun
The New England Journal of Medicine. 2012-05-09
499 citations
Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia
Stefan O. Ciurea, Mei-Jie Zhang, Andrea Bacigalupo, Asad Bashey, Frederick R. Appelbaum
Blood. 2015-08-20
439 citations
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
Bart L. Scott, Marcelo C. Pasquini, Brent R. Logan, Juan Wu, Steven M. Devine
Journal of Clinical Oncology. 2017-02-13

Journal Articles

The European Society for Blood and Marrow Transplantation (EBMT) Consensus Recommendations for Donor Selection in Haploidentical Hematopoietic Cell Transplantation
Leo Luznik, Karen Ballen, Asad Bashey, Hillard M Lazarus, Bipin N Savani, Rizwan Romee, Ephraim J Fuchs, Nature

Abstracts/Posters

Allogeneic Transplantation for Myelodysplastic Syndrome in Adults over 50 Years Old Using Reduced Intensity/Non-Myeloablative Conditioning: Haploidentical Relative Ver...
Asad Bashey, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Graft Versus Host Disease (GVHD) after HLA-Mismatched Haploidentical Transplantation with Post-Transplant Cyclophosphamide Compared to Matched Unrelated Donor: Inciden...
Asad Bashey, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classic...
Asad Bashey, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Phase II Trial of Melphalan Based Reduced Intensity Conditioning and Transplantation of Partially HLA-Mismatched Peripheral Blood Stem Cells for Patients with Hemato...
Asad Bashey, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Real World Outcomes of Letermovir Prophylaxis in Unselected High Risk CMV Seropositive Hematopoietic Stem Cell Transplant Recipients
Asad Bashey, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Psychological and Social Factors Are a Strong Predictor of Survival after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Independent of Disease Risk and Mor...
Asad Bashey, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Reduced Toxicity Conditioning for Non-Malignant Hematopoietic Cell Transplants
Asad Bashey, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Ixazomib Maintenance to Prevent Alloreactivity and Provide Anti-Malignancy Effects Following Nonmyeloablative T-Replete Haploidentical Peripheral Blood Stem Cell Trans...
Asad Bashey, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Improved Survival in Patients Who Undergo Relapse of Acute Myeloid Leukemia Following Allogeneic Hematopoietic Cell Transplantation
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Improved Survival of Patients Diagnosed with Severe (Grade 3-4) Acute GVHD or Severe NIH Grade Chronic GVHD in the Current Era Compared to Historic Controls
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
The Choice of Induction Regimen Affects Post Remission Survival of Acute Myelogenous Leukemia (AML) Patients with Intermediate or Poor Risk Disease
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Evaluation of Romyelocel-L Myeloid Progenitor Cells to Decrease Infections in De Novo AML Patients Receiving High-Dose Ara-C-Based Induction Therapy
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Phase II Study Evaluating the Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem and Progenitor Cells for Allogeneic Hematopoietic Cell Tr...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Join now to see all